Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

REF="http://www.entremed.com" target="_new">http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Patent and Trademark Office (PTO) has issued a patent ... for weight loss. NB32 is a fixed-dose combination of ... U.S. Patent No. 8,815,889 claims methods for treating insulin ... patent expires in 2024. If NB32 is approved for ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ... , M.D., President and Chief Executive Officer, will present at ... Conference in New York on Tuesday, ... A live and archived webcast of the presentation will be ... the "News & Events" section. About Oncothyreon ...
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... The orders consist of three large odour control systems for ... "These orders are consistent with the market resurgence ... Bruijns , President and CEO. "After a difficult period of ... now beginning to see sales growth. Our lower cost structure, ...
(Date:9/2/2014)... 2, 2014  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the United States Patent & ... in the month of August that are part of ... The issued patents are: , U.S.RE45,065 ... 19, 2014; and , U.S.RE45,095 issued August 26, ...
Breaking Biology Technology:Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... Third Wave Technologies is appointing more new ... to a press release. , ,Maneesh Arora, 37, will become ... has held senior positions in marketing and operations for the ... 35, will be vice president of finance. , ,John Bellano, ...
... investments in 2005 added up to more than $19 million ... report released on Wednesday. , ,The investor tax credits offered ... start to officially track the volume of investments by individuals. ... picture we've had of what's going on in the individual ...
... of financing is vital to a biotech company (it is ... "biotech" in the broadest sense) companies are continually faced with ... development cycle, this week's article will focus on venture capital ... on VC financing results from Burrill and Company's data. Burrill's ...
Cached Biology Technology:State tracks more angel investment, at least $19M last year 2U.S. VC funding flat in 2005 while life science funding grows 2U.S. VC funding flat in 2005 while life science funding grows 3U.S. VC funding flat in 2005 while life science funding grows 4
(Date:9/1/2014)... in the U.S. undergoes a battery of tests designed ... disease. Thousands of children born in the developing world, ... from the disease each year. , A.J. Kumar ... of those deaths. , A Post-Doctoral Fellow in ... George Whitesides, the Woodford L. and Ann A. Flowers ...
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... are labeled a “night owl?report more pathological symptoms related ... for their nocturnal sleeplessness by extending their time in ... time, according to a study published in the April ... (JCSM). , The study, authored by Jason C. Ong, ...
... Southwestern Medical Center have found a new method for ... the most common acute infections in children. , ... by tracking down the virus or bacteria causing it. ... virus may not be present in the blood or ...
... Institutes of Health have discovered how a defect in ... several genes interact to create myelin, a fatty coating ... reliability of their electrical signals. , The discovery ... These disorders can affect the peripheral nervous system—the nerves ...
Cached Biology News:'Night owls' report more insomnia-related symptoms 2Infection detectives use disease 'fingerprints' to track common infections in children 2Infection detectives use disease 'fingerprints' to track common infections in children 3Researchers discover gene crucial for nerve cell insulation 2Researchers discover gene crucial for nerve cell insulation 3
Request Info...
FITC~Bovine Serum Albumin...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Biology Products: